MAH0.F Mereo BioPharma Group plc

Healthcare Biotechnology Frankfurt Exchange
0.2680 EUR
Close of Nov 13, 2026
0.1950 1.96
Market cap
EUR 42.8M
P/E
-
P/B
1.97x
ROE
-110.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MAH0.F undervalued?

Graham number

The Graham number of Mereo BioPharma Group plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mereo BioPharma Group plc fundamental analysis

No fundamental analysis for Mereo BioPharma Group plc yet.

Mereo BioPharma Group plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mereo BioPharma Group plc

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autos…

Full company profile